Top

BY Devon Carter

Triple-negative breast cancer (TNBC) makes up 15 to 20 percent of breast cancer diagnoses. The condition often is considered a single disease, when in reality, TNBC is a catch-all diagnosis of biologically different breast cancer subtypes that lack expression of estrogen receptor (ER), progesterone receptor (PR) or human epidermal growth factor receptor 2 (HER2).

In patients with localized disease, a neoadjuvant chemotherapy...

triple-negative breast cancer cells in metaphase during cell division

BY Devon Carter

Over the past decade, immune checkpoint inhibitors have shown success in treating several types of cancer, including melanoma, non-small cell...

BY Ron Gilmore

MD Anderson researchers have discovered that a protein called angiogenin (ANG) serves as a potential biomarker useful for stratifying pancreatic...

BY Ron Gilmore

Somatic mutations in certain genes may function as a molecular minimal residual disease marker for acute myeloid leukemia (AML), according to a study led by Koichi Takahashi, M.D., assistant professor of Leukemia at MD Anderson. The study showed that clearance of somatic mutation at complete response, particularly in non-preleukemic genes, is associated with significantly better overall survival (OS) and cumulative incidence of relapse...

Koichi Takahashi, M.D., reading a medical report